Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anders Osterborg

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
The Hematology Journal : the Official Journal of the European Haematology Association|July 23, 2003
Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and IIIJeanette Lundin, Anders Osterborg, Magnus Björkholm, et al.
Leukemia & Lymphoma|January 19, 2008
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma GroupEva Kimby, Jesper Jurlander, Christian Geisler, et al.
Future Oncology (London, England)|June 6, 2014
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemiaMichael Hallek, Neil E Kay, Anders Osterborg, et al.
Blood|July 20, 2002
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)Jeanette Lundin, Eva Kimby, Magnus Björkholm, et al.
Experimental Hematology & Oncology|February 7, 2014
Opticin, a small leucine-rich proteoglycan, is uniquely expressed and translocated to the nucleus of chronic lymphocytic leukemia cellsEva Mikaelsson, Anders Osterborg, Zahra Tahmasebi Fard, et al.
Cancer Immunology, Immunotherapy : CII|November 17, 2011
Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteriaMarzia Palma, Lotta Hansson, Aniruddha Choudhury, et al.
Leukemia & Lymphoma|October 11, 2012
Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signaturesTherese Högfeldt, Abeer A Bahnassy, Anna Kwiecinska, et al.
Plos One|July 17, 2010
Polycomb target genes are silenced in multiple myelomaAntonia Kalushkova, Mårten Fryknäs, Miguel Lemaire, et al.
Blood|September 17, 2005
IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cellsThomas Strömberg, Simon Ekman, Leonard Girnita, et al.
Blood|March 3, 2005
Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphomaEva Mikaelsson, Amir Hossein Danesh-Manesh, Alfred Lüppert, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
The Hematology Journal : the Official Journal of the European Haematology Association|July 23, 2003
Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and IIIJeanette Lundin, Anders Osterborg, Magnus Björkholm, et al.
Leukemia & Lymphoma|January 19, 2008
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma GroupEva Kimby, Jesper Jurlander, Christian Geisler, et al.
Future Oncology (London, England)|June 6, 2014
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemiaMichael Hallek, Neil E Kay, Anders Osterborg, et al.
Blood|July 20, 2002
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)Jeanette Lundin, Eva Kimby, Magnus Björkholm, et al.
Experimental Hematology & Oncology|February 7, 2014
Opticin, a small leucine-rich proteoglycan, is uniquely expressed and translocated to the nucleus of chronic lymphocytic leukemia cellsEva Mikaelsson, Anders Osterborg, Zahra Tahmasebi Fard, et al.
Cancer Immunology, Immunotherapy : CII|November 17, 2011
Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteriaMarzia Palma, Lotta Hansson, Aniruddha Choudhury, et al.
Leukemia & Lymphoma|October 11, 2012
Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signaturesTherese Högfeldt, Abeer A Bahnassy, Anna Kwiecinska, et al.
Plos One|July 17, 2010
Polycomb target genes are silenced in multiple myelomaAntonia Kalushkova, Mårten Fryknäs, Miguel Lemaire, et al.
Blood|September 17, 2005
IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cellsThomas Strömberg, Simon Ekman, Leonard Girnita, et al.
Blood|March 3, 2005
Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphomaEva Mikaelsson, Amir Hossein Danesh-Manesh, Alfred Lüppert, et al.
Pageof 8